GlassScriptPhysician profile
Raghuveer M Reddy
NPI 1619979101
$891.34
in general payments reported to CMS, 2019-2025
8 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $49.96 · 2021: $161 · 2022: $77.99 · 2023: $137 · 2024: $201 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $473.38 | 2019-2025 | Epclusa |
| Abbvie INC. | $200.89 | 2023-2025 | |
| Evoke Pharma, INC. | $77.98 | 2023-2024 | Gimoti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.17 | 2024 | Imfinzi |
| Madrigal Pharmaceuticals | $25.31 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $23.80 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.94 | 2024 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raghuveer Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.